ONCONETIX INC (ONCO)
US09610B1089 - Common Stock
We assign a fundamental rating of 0 out of 10 to ONCO. ONCO was compared to 576 industry peers in the Biotechnology industry. Both the profitability and financial health of ONCO have multiple concerns. ONCO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ONCO had negative earnings in the past year.
In the past year ONCO has reported a negative cash flow from operations.
ONCO had negative earnings in each of the past 5 years.
ONCO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ONCO has a Return On Assets of -60.89%. This is in the lower half of the industry: ONCO underperforms 60.03% of its industry peers.
ONCO has a Return On Equity (-106.99%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.89% | ||
| ROE | -106.99% | ||
| ROIC | N/A |
ROA(3y)-75.1%
ROA(5y)-57.66%
ROE(3y)-134.27%
ROE(5y)-93.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ONCO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ONCO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONCO has more shares outstanding than it did 1 year ago.
ONCO has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.25, we must say that ONCO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.25, ONCO perfoms like the industry average, outperforming 50.26% of the companies in the same industry.
A Debt/Equity ratio of 0.36 indicates that ONCO is not too dependend on debt financing.
The Debt to Equity ratio of ONCO (0.36) is worse than 71.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.25 |
ROIC/WACCN/A
WACC6.14%
2.3 Liquidity
ONCO has a Current Ratio of 0.29. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
ONCO has a Current ratio of 0.29. This is amonst the worse of the industry: ONCO underperforms 96.34% of its industry peers.
ONCO has a Quick Ratio of 0.29. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
ONCO's Quick ratio of 0.28 is on the low side compared to the rest of the industry. ONCO is outperformed by 96.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.29 | ||
| Quick Ratio | 0.28 |
3. Growth
3.1 Past
The earnings per share for ONCO have decreased strongly by -138.90% in the last year.
EPS 1Y (TTM)-138.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-178.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -14.13% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.84%
EPS Next 2Y-14.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ONCO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ONCO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ONCO's earnings are expected to decrease with -14.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.13%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ONCO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ONCONETIX INC
NASDAQ:ONCO (7/1/2024, 2:19:01 PM)
0.156
-0.01 (-6.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.48M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.89% | ||
| ROE | -106.99% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.29 | ||
| Quick Ratio | 0.28 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-138.9%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-11.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y